• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Zura Bio Ltd.

Headquarters: San Diego, CA, United States
Website: https://zurabio.com/
Year Founded: 2022
Status: Public
Industry Sector: HealthTechnology
CEO: Robert Lisicki
Number Of Employees: 30
Enterprise Value: $24,382,903
PE Ratio: -2.08
Exchange/Ticker 1: NASDAQ:ZURA
Exchange/Ticker 2: N/A
Latest Market Cap: $83,417,504

BioCentury | Mar 29, 2025
Product Development

Bispecifics for I&I: Bypassing combination complexity

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
Read More
BioCentury | Jan 18, 2025
Product Development

2025 catalysts: New I&I indications take center stage

Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
Read More
BioCentury | Aug 3, 2024
Deals

Biotechs find problem-solving in academia, and mostly outside the big hubs 

Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
Read More
BioCentury | Apr 19, 2024
Finance

Public equity report: Depression data drive Intra-Cellular’s $500M raise

Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura
Read More
BioCentury | Apr 8, 2024
Management Tracks

Chi Li to lead regulatory at Curevo

Plus: Zura names Robert Lisicki as CEO, and updates from Faron, IO, PanTher and Precision
Read More
BioCentury | Jan 10, 2024
Management Tracks

Mark Alles at the helm at Torl

Plus: new CSO at Nutcracker, and updates from 
Read More
BioCentury | Oct 25, 2023
Management Tracks

CFO Joanne Bryce to depart Disc

Plus: Jeff Albers joins Scorpion as strategic adviser, and updates from Mironid, 1859, mbiomics and Tevogen
Read More
BioCentury | Apr 27, 2023
Finance

April 27 Finance Quick Takes: Therini raises $36M A for fibrin-targeted therapies

Plus: Zura raises $80M, adds bifunctional asset in Lilly deal and updates from Foresite Diagnostics, Adcentrx, Pattern, Antiva and Mezzion
Read More
BioCentury | Apr 14, 2023
Management Tracks

Dewhurst leaving McKinsey after 30 years

Plus: Sabet-Peyman now partner at Patient Square and an update from Zura Bio
Read More
BioCentury | Apr 13, 2023
Management Tracks

SVB’s Sabow to lead HSBC tech, healthcare business 

Plus: Century revamps C-suite amid CEO departure and updates from Bausch + Lomb, Gennao, Celares, Sherlock, Viridian and more
Read More
Items per page:
1 - 10 of 12
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa